Tebipenem: A Novel Oral Carbapenem

Archana Mahalingam¹, Bhaskar Shenoy²

Abstract

Carbapenems are an important class of drugs very much useful in the therapy of multidrug-resistant gram-negative pathogens. Though these are available for the past 30 years, they can be administered only parenterally, which can reduce the compliance. Tebipenem-pivoxil (TBPM-PI; Orapenem), a prodrug, is the first oral carbapenem. It has been a promising drug in the therapy of drug-resistant respiratory infections and complicated urinary tract infections. It will also be useful in reducing the incidence of central line associated bloodstream infections (CLABSI) and improving the rate of treatment completion.

Keywords: Carbapenem, Complicated urinary tract infections, Penicillin-resistant Streptococcus pneumonia, Recurrent respiratory infections.

Introduction

Carbapenems are great drugs for management of multidrug-resistant gram-negative pathogens. They belong to a subclass of beta-lactam antibiotics with broadest spectrum of activity and better beta-lactamase stability. Though these effective drugs are available for over 30 years, treatment of these infections is challenging as majority of available carbapenems can be administered only parenterally, hence compliance becomes jeopardized. Tebipenem-pivoxil (TBPM-PI; Orapenem), a prodrug, is the first oral carbapenem. It was first developed by Pfizer Inc. (New York, NY, USA).¹ It is approved in Japan for use in children in 2009 and is currently marketed only in Japan (Meiji Seika Pharma Co., Ltd, “Meiji”) as a granule formulation (Orapenem Fine Granules 10%) for pediatric use. In complicated serious resistant gram-negative infections, this provides an option for oral step down.²

Chemistry

The first carbapenem structure, thienamycin, which is a natural product derived from Streptomyces cattleya, was isolated in 1976. Subsequently, parenteral carbapenem agents, such as imipenem, panipenem, meropenem, and biapenem, were developed based on this parent compound for the treatment of severe bacterial infections.³

In TBPM-PI, tebipenem (TBPM;SPR859) is the active moiety.² This is esterified to TBPM-PI by adding the pivaloyloxymethyl group to carboxylic acid at the C-2 position (Fig. 1).⁴ This prodrug with pivaloyloxymethyl ester has a higher absorption rate when compared to other prodrugs of beta-lactam antibiotics and gets quickly hydrolyzed to the active antimicrobial agent.⁵

Mechanism of Action

Tebipenem passes through the outer membrane into the periplasmic space like other beta-lactam antibiotics. The penicillin-binding proteins (PBPs) are inhibited after acylation of tebipenem in the periplasmic space. Thus, the formation of cell wall peptidoglycan is catalyzed and thus weakens the peptidoglycan, which results in lysis of the bacterial cell.

Figs 1A and B: Chemical structures: (A) Tebipenem-pivoxil; (B) Tebipenem⁴,⁵
In *S. pneumoniae*, the C-2 side chain of tebipenem formed key hydrophobic interactions with PBPs 2X and 1A, which are the key conserved residues in the PBPs in *Streptococcus pneumoniae*. The binding affinity to *Haemophilus influenzae* PBPs is also high. The conserved residues in the PBPs in *Streptococcus pneumoniae* hydrophobic interactions with PBPs 2X and 1A, which are the key.

**Spectrum of Activity**

It has broad spectrum in vitro and in vivo activity against gram-negative and gram-positive pathogens, including resistant bugs like extended spectrum β-lactamases (ESBL)-producing Enterobacteriaceae and strains resistant to fluoroquinolones and trimethoprim sulfamethoxazole. The antibacterial activity of TBPM-PI is more efficacious than other carbapenems against infections in children caused by penicillin-resistant *Streptococcus pneumoniae* (PRSP), macrolide-resistant *Streptococcus pneumoniae* (MRSP) and *Haemophilus influenzae* (Hib), and B-lactamase-nonproducing ampicillin-resistant *H. influenzae* (BLNAR). The bactericidal activity of tebipenem against *S. pneumoniae* and *H. influenzae* is comparable to that of levofloxacin and cefditoren. Even *Burkholderia pseudomallei*, a gram-negative pathogen causing melioidosis, is inhibited by tebipenem with minimum inhibitory concentrations (MICs) of 1–2 μg/mL. Tebipenem has potent activity against *Neisseria gonorrhoeae*, which is comparable to cefixime that has the most potent activity among oral antibiotics.

The MIC₉₀ reported for *Acinetobacter baumannii*, *Serratia marcescens*, and *P. aeruginosa* is higher than for meropenem and hence better to avoid tebipenem use for these bugs.

Aerobes including *Preptostreptococcus* spp., *Bacteroides fragilis* (MIC₉₀ ≤ 1 μg/mL), and *Clostridium difficile* (MIC₉₀ = 1 μg/mL) are susceptible to tebipenem. It is also effective against *Clostridium perfringens*, *Veillonella* spp., *Prevotella* spp., *Porphyromonas* spp., and *Fusobacterium* spp. (MIC₉₀ ≤ 0.25 μg/mL).

**Pharmacokinetics and Pharmacodynamics**

The absorption and bioavailability are better with this prodrug form when compared to other carbapenems and has sufficient stability against hDHP-I in its active form. From the studies in mice, it is shown that the tablet form has better bioavailability than the granules form. After absorption of the produg in the

<table>
<thead>
<tr>
<th>Strain</th>
<th>MIC₅₀/MIC₉₀ (μg/mL)</th>
<th>TBPM-PI</th>
<th>Meropenem</th>
<th>Imipenem and cilastin</th>
<th>Ceftriaxone</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MSSA</strong></td>
<td>≤0.125/≤0.125</td>
<td>≤0.125/0.25</td>
<td>≤0.125/2</td>
<td>2/4</td>
<td></td>
</tr>
<tr>
<td><strong>MRSA</strong></td>
<td>8/16</td>
<td>32/128</td>
<td>&gt;128/128</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>MSSE</strong></td>
<td>≤0.125/0.5</td>
<td>≤0.125/1</td>
<td>≤0.125/1</td>
<td>1/16</td>
<td></td>
</tr>
<tr>
<td><strong>MRSE</strong></td>
<td>8/8</td>
<td>16/64</td>
<td>64/128</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Enterococcus faecalis</strong></td>
<td>0.25/32</td>
<td>2/&gt;128</td>
<td>4/&gt;128</td>
<td>32/&gt;128</td>
<td></td>
</tr>
<tr>
<td><strong>Enterococcus faecium</strong></td>
<td>64/128</td>
<td>&gt;128/&gt;128</td>
<td>&gt;128/&gt;128</td>
<td>&gt;128/&gt;128</td>
<td></td>
</tr>
<tr>
<td><strong>Pyogenic streptococcus</strong></td>
<td>≤0.125/≤0.125</td>
<td>≤0.125/≤0.125</td>
<td>≤0.125/1</td>
<td>1/4</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Strain</th>
<th>MIC₅₀/MIC₉₀ (μg/mL)</th>
<th>Tebipenem Pivoxil</th>
<th>Meropenem</th>
<th>Imipenem and Cilastin</th>
<th>Ceftriaxone</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Escherichia coli</strong></td>
<td>≤0.125/1</td>
<td>≤0.125/1</td>
<td>0.25/1</td>
<td>64/&gt;128</td>
<td></td>
</tr>
<tr>
<td><strong>Klebsiella pneumonia</strong></td>
<td>≤0.125/0.5</td>
<td>≤0.125/1</td>
<td>0.5/4</td>
<td>2/&gt;128</td>
<td></td>
</tr>
<tr>
<td><strong>Enterobacter cloacae</strong></td>
<td>≤0.125/1</td>
<td>≤0.125/2</td>
<td>0.25/2</td>
<td>128/&gt;128</td>
<td></td>
</tr>
<tr>
<td><strong>Enterobacter aerogenes</strong></td>
<td>≤0.125/≤0.125</td>
<td>≤0.125/0.25</td>
<td>0.5/2</td>
<td>0.5/32</td>
<td></td>
</tr>
<tr>
<td><strong>Acinetobacter baumannii</strong></td>
<td>32/64</td>
<td>64/128</td>
<td>128/&gt;128</td>
<td>&gt;128/&gt;128</td>
<td></td>
</tr>
<tr>
<td><strong>S. maltophilia</strong></td>
<td>32/64</td>
<td>128/&gt;128</td>
<td>&gt;128/&gt;128</td>
<td>&gt;128/&gt;128</td>
<td></td>
</tr>
<tr>
<td><strong>Pseudomonas aeruginosa</strong></td>
<td>8/64</td>
<td>16/128</td>
<td>128/&gt;128</td>
<td>&gt;128/&gt;128</td>
<td></td>
</tr>
<tr>
<td><strong>Serratia marcescens</strong></td>
<td>≤0.125/16</td>
<td>≤0.125/32</td>
<td>2/64</td>
<td>8/&gt;128</td>
<td></td>
</tr>
<tr>
<td><strong>H. influenzae</strong></td>
<td>≤0.125/0.25</td>
<td>≤0.125/0.5</td>
<td>≤0.125/1</td>
<td>2/16</td>
<td></td>
</tr>
<tr>
<td><strong>Proteus mirabilis</strong></td>
<td>≤0.125/≤0.125</td>
<td>≤0.125/0.5</td>
<td>≤0.125/0.5</td>
<td>16/64</td>
<td></td>
</tr>
</tbody>
</table>
Tebipenem: A Novel Oral Carbapenem
gastrointestinal tract, carboxyesterase in the intestinal epithelial cells converts the prodrug to its active form TBPM. This is then transferred to the blood circulation. The intestinally expressed transporters like OATP1A2 and OATP2B1 facilitate the absorption and this tebipenem has a high oral availability of 35–70%. The urinary tract exposure is as high as 54–73% of active tebipenem along with 80% of its metabolites are excreted in the urine after oral dosing in humans; thus, TBPM is highly distributed in kidneys. There is constant excretion of TBPM-PI without accumulation.

It has poor penetration in the central nervous system. There is effective transfer of tebipenem from plasma to middle ear fluid also. Serum protein binding of TBPM in the range of 0.1–100 μg/mL was 59.7–73.9% for humans. The peak plasma concentrations of tebipenem reached 0.7 hour after oral administration of TBPM-PI and the plasma concentrations decreased by half every 1 hour.

In general, for beta-lactams, T > MIC is considered as a PK–PD parameter. In carbapenem antibiotics, a favorable clinical outcome can be predicted when a free antibiotic in plasma has a T > MIC value ≥25%. However, for TBPM PI, AUC/MIC rather than T > MIC predicts the bacteriological efficacy. Tebipenem has a linear pharmacokinetics within the expected dosing range. Linearity was noted between Cmax of TBPM and the TBPM-PI doses from 100 to 200 mg and between AUC0-∞ of TBPM and TBPM-PI doses from 100 to 500 mg.

**CLINICAL USE**

Tebipenem-pivoxil is licensed for use in otolaryngologic infections and respiratory infections in children. It is useful in the treatment of prolonged or recurrent infections due to PRSP and/or *H. influenzae* in children, as these are difficult to be cured with the currently clinically available antibiotics. In particular, TBPM possesses a strong antibiotic activity against PRSP, which causes intractable pediatric otitis media. Its therapeutic efficiency is significantly higher than imipenem, amoxicillin, and levofloxacin. It can be used in cases in whom standard therapeutic antimicrobial drugs are not expected to be effective.

In Japan, TBPM-PI is the drug of choice in pneumonia caused by *S. pneumoniae*, which is penicillin- and macrolide-resistant and beta-lactamase nonproducing ampicillin-resistant *H. influenzae*. In a study on 3,331 pediatric patients, the overall clinical efficacy of tebipenem was 94% (pneumonia—95.6%, otitis media—93.7%, sinusitis—93.6%). The eradication rates of *S. pneumoniae*, *H. influenzae*, and *M. catarrhalis*, which are major causative organisms of pneumonia, otitis media, and sinusitis in children, were 94.4, 92.2, and 97.8%, respectively. Even the compliance was good in 83.1% of these patients.

Tebipenem has a superior bactericidal activity against *S. pneumoniae*, which was evident by rapid decrease in body temperature and the reduction in leukocyte counts and CRP levels. Dose of 6 mg/kg bid has higher efficacy and is useful based on symptoms and severity. The 3 day TBPM-PI regimen was shown to cure all cases of bacterial pneumonia in children except in pneumonia caused by MRSA. A 3 day course of TBPM-PI at 6 mg/kg/dose twice daily was very effective in treating pneumonia in those without immunocompromised state or without complications. The short duration of oral therapy improves the compliance, reduces chances of the bacterial resistance, adverse effects, and cost of therapy.

The recommended dosage for children is 4 mg/kg/dose, 12th hourly, and the dose can be increased to the maximum dose of 6 mg/kg/dose, 12th hourly. In pediatric patients at risk for the aggravation or prolongation of otitis media caused by resistant bacteria, who are less than 2-years-old, who are under group nursing, who have received at least one antibiotic, who are concurrently affected by rhinosinusitis, and who have a history of otitis media, the maximum dose can be considered.

The peak points of 1 μg/mL, 2 μg/mL, and 4 μg/mL are considered for interpretation of susceptible, intermediate, and resistant strains of *S. aureus* and *H. influenzae*.

**ADVERSE EFFECTS AND DRUG INTERACTIONS**

Despite tebipenem being a broad-spectrum oral antibiotic, it has minimal effect on gut organisms after 5 days of BD dosing. The development of antibiotic-resistant organisms with this drug was minimal.

Tebipenem-pivoxil is considered to be safe at dosage of 4 mg/kg bid in pediatric patients. The common adverse effects associated with tebipenem are watery stools, mushy diarrhea (9.52%), and trombocytosis. No severe or serious adverse drug reactions were seen.

Carbapenems are known to reduce valproic acid (VPA) concentration in the blood when VPA and injectable carbapenem antibiotics are coadministered. Even tebipenem has similar concentration in the blood when VPA and injectable carbapenem are considered for interpretation of susceptible, intermediate, and resistant strains of *S. aureus* and *H. influenzae*.

**CONCLUSION**

There are strong expectations for TBPM-PI in the treatment of drug-resistant pediatric infections. However, since it is the first oral carbapenem antimicrobial drug, its use should be limited from the viewpoint of preventing the emergence of resistant bacteria. Its indications should be narrowed down to refractory pediatric otitis media, sinusitis, and pneumonia due to drug-resistant bacteria.

**REFERENCES**